​Albert Adell, PhD is Principal Investigator of the Systems Neurobiology Group at the Institute of Biomedicine and Biotechnology of Cantabria, a joint center Joint Centre belonging to the National Research Council (CSIC), the University of Cantabria, and the Regional Government through its Society for the Development of Cantabria (SODERCAN). Dr. Adell was awarded a Bachelor of Science degree in Biology from the University of Barcelona (1981) and a PhD degree in Biology from the same Institution (1986). In 1987 he earned a postdoctoral position at Professor Gerald Curzon's Lab at the Institute of Neurology (London, UK), where he learned the intricacies of the in vivo microdialysis technique that allows the measurement of neurotransmitters release in the brain of behaving animals. In 1990 he earned a position as tenured scientist from the Spanish National Research Council, and he started to study the mechanism of action of antidepressant drugs at the Institute of Biomedical Research of Barcelona. In 1991 he continued to study the role of raphe nuclei in the mechanism of action of antidepressant drugs as a Visiting Scientist at the Department of Pharmacology of the School of Medicine of the University of Gothenburg (Sweden). In 1993 he was appointed as Research Scholar at the Department of Pharmacology of the School of Medicine of the East Carolina University (NC, USA) where he spent two years teaching graduate students and studying the role of brain monoamines in alcohol addiction. Back to Spain in 1995, he continued to examine the effects of antidepressant and antipsychotic drugs on brain monoamines and behavior. In 2009 he promoted to Research Scientist from the Spanish National Research Council and eventually moved to the Institute of Biomedicine and Biotechnology of Cantabria in 2014. His main interest is the study of new molecular entities that can act as rapid-acting antidepressant drugs (RAADs).